Overview

Geodon for the Treatment of Refractory Social Anxiety Disorder

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone
Phase:
Phase 2
Details
Lead Sponsor:
Duke University
Collaborator:
Pfizer
Treatments:
Sertraline
Ziprasidone